Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
US6890921B1 · kind B1 · utility
0Cited by
6References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2000 |
| Grant date | May 10, 2005 |
| Priority date | — |
| Expiry date | Jan 11, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention relates to a series of arylsubstituted piperazines, of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.